Five months gone, no clue, which can be a likely solution to the global pandemic that is still hurting the economies of different countries.
There are over 3,459,900 positive cases worldwide, with over 243,457 deaths confirmed in over 200 countries around the world.
Given the strong urge from different countries to reopen the laid-off economy, there is a high demand for an immediate cure or a vaccine. While many research institutes have entered the race to find solution and save the world, so far it seems there is no good news yet.
Previously, there was some hope that Remdesivir, a drug manufactured by a company in California and intended for the treatment of Ebola, had shown results in the treatment of COVID-19. However, a research institute in China published that it failed in randomized trials.
Being no other drug, the U.S. Food and Drug Administration (FDA) has approved Remdesivir as an emergency treatment of coronaviruses.
This implies that the drug can now be used to treat COVID-19 patients who are based in various hospitals in the United States.
Clinical trials have been conducted in the US showing that COVID-19 patients recovered faster than others after the antiviral drug was injected. However, the drug was unable to prove in a test that it can increase survival rates.
Experts have warned against using this medicine to treat coronavirus.
The drug has been claimed to disrupt the viral genome and interfere with its replication ability.
The managing director of Gilead, the manufacture of Remdesivir, sees the approval of the drug as an important step. Daniel O’Day, during a meeting with the President of the United States, confirmed that the company would donate 1.5 million vials of the drug.
FDA commissioner Stephen Hahn was also proud of the approval of the drug for the treatment of COVID-19.
However, it is a half-hope for the world that needs a COVID-19 cure. The antiviral drug has only been approved as an emergency solution, but not as a formal solution that requires a higher level of review.
Also, as it missed its intended purpose of treating Ebola, it should be used as an experimental medicine since its safety or effectiveness in treating disease has not yet been approved.
The US president was a vocal proponent of the drug as a potential treatment for the novel coronavirus. The virus has killed 66,819 people in the United States, with over 1.14 million cases reported nationwide.
Although Remdesivir may help recover from COVID-19 infection and, in return, help stop or reduce the number of people to be sent to the intensive care unit, the drug cannot prevent deaths from the virus.
Even recovery is not so instantaneous but is relatively shorter compared to patients without Remdesivir administration. Its manufacturer, Gilead, recommends a 10-day dosing period for ventilated patients and five days for those who do not.
It will remain uncertain whether the drug will be effective, efficient, or vice versa, even if other countries in the world join the US to raise hopes for this antiviral drug.
Lena Wood graduated from John Carroll University in the year 2002. She born and grown up in Dallas but later she moved to Cleveland for Studying. Lena has written for several major publications including Community Newspapers and News Desk. Lena is a community Reporter and also Covers National Topics.